BioTime to Present Data at the Military Health System Research Symposium
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 28, 2017--
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology
company focused on developing and commercializing products addressing
degenerative diseases, today announced that it will be presenting one
podium presentation and two abstracts at the Military Health System
Research Symposium (MHSRS) August 27-30, 2017 in Washington, D.C.
BioTime has recently released data from its two lead programs in medical
aesthetics and ophthalmology and is now exploring ways to address
serious unmet needs for trauma and combat-related injuries.
The podium presentation and two abstracts include:
The podium presentation titled, “Restoring Light Perception with
Retinal Tissue Grafting Derived from Human Pluripotent Stem Cells”
will be presented by Dr. Igor Nasonkin, BioTime’s head of research, on
Monday, August 28th during the Medical Advancements in
Operational and Clinical Vision Protection and Treatment session. This
presentation outlines the potential use of BioTime’s pluripotent cell
technology to help the body restore vision following blast exposure.
The preclinical study demonstrates positive results following grafting
of these cells into sub-retinal tissue, as well as improvement in
tracking vision over an eight month period.
The abstract titled, “Repair of Trauma-Induced Subcutaneous Contour
Defects Using Autologous Adipose Derived Stem Cells Implanted in
Renevia® Hydrogel Matrix” will be
presented by Dr. Thomas Zarembenski, BioTime’s head of external R&D,
on Tuesday, August 29th during the Head, Neck & Facial
Trauma/ Otolaryngology & Plastic Surgery Demo session. This abstract
describes safety data following the use of Renevia® in facial contour
defects as a result of trauma.
The abstract titled, “Vision Preservation Following Blast Injury
Through Continuous Paracrine Delivery of Trophic Factors to
Degenerating Optic Nerve and Retina” will be presented by Dr.
Nasonkin, on Tuesday, August 29th during the Medical
Advancements in Operational and Clinical Vision Protection and
Treatment session. This abstract outlines two methodologies used to
differentiate pluripotent cells, followed by their implantation in
mouse models with degenerating optic nerve and retinal tissue. The
study demonstrates successful, tumor-free integration with retinal
tissue, which is expected to slow, halt or improve vision degeneration
“The MHSRS symposium is hosted by the Department of Defense (DoD) and it
highlights medical solutions that may lead to therapies to further
protect troops and veterans,” said Adi Mohanty, co-CEO of BioTime. “We
believe our technologies can help address issues associated with trauma,
reconstruction or other combat-related injuries. We look forward to
working with the Department of Defense towards expanding the potential
uses of our platforms and products.”
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on developing
and commercializing products addressing degenerative diseases. Its
clinical programs are based on two platform technologies: pluripotent
cells and cell/drug delivery. The foundation of BioTime’s core
therapeutic technology platform is pluripotent cells that are capable of
becoming any of the cell types in the human body. The foundation of the
Company’s cell delivery platform is its HyStem® cell and drug delivery
matrix technology. The Company’s current clinical programs are targeting
three primary sectors, aesthetics, ophthalmology and cell/drug delivery.
BioTime also has significant equity holdings in two publicly traded
companies, Asterias Biotherapeutics, Inc. and OncoCyte Corporation.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com or
connect with the company on Twitter, LinkedIn, Facebook, YouTube,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotimeinc.com.
Certain statements contained in this release are “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development, and potential opportunities for BioTime, Inc. and its
subsidiaries, along with other statements about the future expectations,
beliefs, goals, plans, or prospects expressed by management constitute
forward-looking statements. Any statements that are not historical fact
(including, but not limited to statements that contain words such as
“will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the business of BioTime, Inc. and its
subsidiaries, particularly those mentioned in the cautionary statements
found in more detail in the “Risk Factors” section of its Annual Reports
on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC
(copies of which may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. BioTime specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005249/en/
Source: BioTime, Inc.
David Nakasone, 510-871-4188
Michael Polyviou, 646-445-4800
JQA Partners, Inc.
Jules Abraham, 917-885-7378